Close Menu

NEW YORK — Abcam said on Thursday that it has acquired the gene editing platform and oncology product portfolio of Applied StemCell for the research and diagnostic markets.

According to Abcam, the deal includes Applied StemCell's portfolio of cell lines and its AccuRef reference materials product line, which is used to mimic cancer mutations and create biologically relevant quality control and reference standards for over 40 cancer genes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.